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In the 27 years since Fixx's death, scientists from many disciplines have published an enormous body of work on the physiological and metabolic effects of exercise. Higher levels of physical activity and exercise capacity are correlated with lower levels of blood pressure, heart rate, and tendency to thrombosis, and with higher levels of parasympathetic tone, cardiovascular reserve, endogenous thrombolysis, and endothelial function. 2 Population-based and clinical epidemiological investigators have consistently observed a strong and inverse association between exercise capacity and adverse health outcomes. 3 Scientists from the Cooper Clinic have been among the leaders in showing that men and women with greater exercise capacity have lower rates of all-cause mortality and cardiovascular mortality, and that these associations are independent of age, traditional cardiovascular risk factors, and obesity. 4 The Cooper Clinic work has focused on clinically healthy adults being evaluated in a preventive medicine setting. Other investigators have shown remarkably similar inverse associations of exercise capacity and clinical events in other settings, including among patients undergoing myocardial perfusion studies 5 and heart transplant evaluations. 6 In addition, in the 27 years since Fixx's death, cardiovascular scientists have made progress on other fronts. We have discovered predictors of cardiovascular events, including circulating biomarkers of inflammation and hormonal stress, as well as findings on different imaging modalities. On the basis of numerous large-scale randomized, controlled trials, we now know that we can prevent cardiovascular events and deaths in certain patient groups 7 with aspirin, ␤-blockers, angiotensin-converting enzyme inhibitors, thiazide diuretics, statins, thrombolytics, coronary revascularization, and implantable defibrillators. With so many diagnostic and prognostic tools available to us, is there a role of exercise capacity for cardiovascular prediction? In addition, and this is perhaps a more important question, armed with so many randomized, controlled trial-proven effective interventions-what is the role of exercise as a therapeutic or preventive modality?
Over the past 20 to 30 years, epidemiologists have typically tested the predictive value of hypothesized risk factors and markers by constructing statistical regression models. If a risk factor or marker retained a statistically significant association with an outcome even after other known predictors were included in a model, it could be declared an independent predictor. This construct has led to an unsatisfactory state of affairs, with publications demonstrating the existence of literally hundreds of cardiovascular risk factors. 8 Some have argued that statistical modeling fails to account for the biological pathway by which a candidate risk factor may lead to, or merely correlate with, disease. 8 Others have argued that traditional regression modeling is overly sensitive, allowing for relatively weak predictors to be deemed independent, leaving clinicians unable to determine their ability to provide meaningful incremental information. Two years ago, the American Heart Association released a Scientific Statement that called for much higher standards for purported risk factors. 9 Statistical significance is now only a start; scientists must also demonstrate that their risk factors substantially improve risk discrimination (the ability to distinguish between patients who will and will not experience events) or reclassification (the ability to accurately predict level of risk). Using newer statistical approaches, investigators have shown that coronary calcium substantially improves risk prediction, 10 whereas, despite much fanfare, the genetic marker 9p21.3 does not. 11 Interestingly, another group of investigators found, contrary to their expectations, that exercise capacity does not improve predictive discrimination or reclassification of sudden cardiac death. 12, 13 Is it possible that Dr Ascheim's question was not so off base?
In the current issue of Circulation, Gupta et al 14 statistical approaches to assess the association of exercise capacity with cardiovascular risk. In a true tour de force, the investigators performed exercise testing in Ͼ66 000 adults, who were then followed for a mean of 16 years. The authors found that, even after accounting for numerous possible confounders, exercise capacity substantially improved discrimination and reclassification for predicting all-cause and cardiovascular mortality. The strengths of the study include its use of standardized symptom-limited exercise testing, its enormous sample size with an attendant large number of hard clinical events, and its high rate of continuous follow-up. When this study is combined with prior literature, there can be little doubt that exercise capacity is a meaningful predictor of cardiovascular risk. As powerful as these data are, we are still left with a fundamental unanswered question. What are the health benefits of exercise, and who are the people most likely to realize them? Although merely asking this question may seem almost heretical, we have seen many cases in which prediction did not correctly imply prevention. Elevated levels of homocysteine consistently predict risk, yet homocysteinelowering therapy does not prevent events. 15 Oxidative stress predicts risk, yet, at least so far, antioxidants do not prevent events. 16 Among patients with diabetes mellitus, higher glucose and glycohemoglobin levels predict risk, yet intensive glucose-lowering therapy has questionable benefits. 17 For each of these cases, and many others, we needed large-scale randomized, controlled trials to determine whether epidemiological associations and biological pathways did or did not translate into effective clinical interventions.
Where are we with exercise capacity? Despite an extraordinary body of literature demonstrating the ability of exercise capacity to predict cardiovascular risk, we have few largescale randomized trial data showing that interventions that improve exercise capacity prevent clinical events. One trial cited by Gupta et al failed to show a statistically significant reduction in risk among survivors of acute myocardial infarction. 18 Another trial showed that even low levels of exercise, levels that are well below current recommendations, can improve exercise capacity, 19 but in this trial, exercise capacity acted only as a surrogate end point. The Diabetes Prevention Program trial showed that lifestyle interventions that include exercise can prevent progression to diabetes mellitus in patients with glucose intolerance. 20 The ongoing LookAhead trial (NCT00017953) is testing whether lifestyle interventions including exercise can prevent major cardiovascular events in patients with established diabetes mellitus. The large Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial in patients with heart failure demonstrated a modest degree of clinical benefit, 21 but, as with the diabetes trials, we do not know whether we can extrapolate these findings to the general public or to patients with less severe degrees of disease.
Even if exercise interventions improve outcome in some people with low levels of exercise capacity, it is not clear that these interventions would have a substantial impact on public health. Within Gupta's cohort, men classified as high risk according to a model that included exercise capacity accounted for only 17% of 25-year cardiovascular deaths; most events occurred in people who were classified as low to intermediate risk. Rose 22 showed that this is a common phenomenon for many risk factors, and that the best way to reduce burden of disease is through population, not clinical, interventions. We can increase population exercise capacity through a variety of policy approaches, including fostering economic and built environments that incentivize physical activity. It is difficult, although not impossible, to perform randomized trials of population interventions; an acceptable alternative approach is to take advantage of natural experiments (or quasi-experiments), as some investigators have applied to assessment of passive smoking interventions. 23 Eight years ago, Daniel Mark and I noted in these pages that exercise capacity is a prognostic variable that "doesn't get enough respect." 3 We must admit that we have made only limited progress since Dr Ascheim commented after Jim Fixx's death that we really do not know the health benefits of exercise. Armed with the pioneering work of Gupta et al and the few trials done to date, we have a strong hypothesis that exercise interventions, whether implemented in clinical or population settings, improve health and prevent cardiovascular events over and above the benefits realized by already proven interventions. We are now ready to move the next phase of exercise research, which should emphasize largescale randomized practical trials of different types and doses of exercise interventions in varying populations of patients and healthy people. Only then will exercise capacity "get enough respect," and will we be able to provide appropriately targeted patients and the general public with the kind of robust evidence-based care and policy interventions they deserve.
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